Media headlines about Collegium Pharmaceutical (NASDAQ:COLL) have trended somewhat positive on Thursday, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Collegium Pharmaceutical earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 48.0966153114322 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research upgraded Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Needham & Company LLC reiterated a “buy” rating and issued a $25.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, June 9th. Janney Montgomery Scott reiterated a “buy” rating and issued a $25.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, June 12th. Piper Jaffray Companies set a $14.00 price objective on Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Tuesday, July 25th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $22.00 price objective (down from $24.00) on shares of Collegium Pharmaceutical in a research report on Thursday, May 11th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $21.33.

Collegium Pharmaceutical (NASDAQ COLL) traded up 2.97% during midday trading on Thursday, hitting $10.04. The company had a trading volume of 300,660 shares. The company’s market capitalization is $296.84 million. Collegium Pharmaceutical has a 52 week low of $7.37 and a 52 week high of $20.55. The stock has a 50 day moving average price of $11.08 and a 200 day moving average price of $11.37.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.09. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%. The firm had revenue of $3.56 million for the quarter, compared to the consensus estimate of $4.07 million. Equities analysts forecast that Collegium Pharmaceutical will post ($3.00) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Collegium Pharmaceutical (COLL) Given Coverage Optimism Score of 0.17” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Insider Buying and Selling by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Stock Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.